Zai Lab Limited (ZLAB)
(Real Time Quote from BATS)
$18.48 USD
+0.48 (2.67%)
Updated Jul 16, 2024 01:42 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Price, Consensus and EPS Surprise
ZLAB 18.48 +0.48(2.67%)
Will ZLAB be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ZLAB based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ZLAB
Best Momentum Stocks to Buy for July 10th
New Strong Buy Stocks for July 10th
ZLAB: What are Zacks experts saying now?
Zacks Private Portfolio Services
What Makes Zai Lab Limited Unsponsored ADR (ZLAB) a New Buy Stock
Ultragenyx (RARE) Surges 10.3%: Is This an Indication of Further Gains?
Seagen's (SGEN) Late-Stage Cervical Cancer Study Meets Goals
Other News for ZLAB
Zai Lab and argenx Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China
Zai Lab-Supported Study Published in Cell Provides New Insights with Potential to Improve Treatment of HRD-Positive Ovarian Cancers, Including Through Combination PARP Inhibitor and CCR8 Therapy
Zai Lab to Announce Second Quarter 2024 Financial Results and Recent Corporate Updates on August 6, 2024
Insider Selling: Chairperson & CEO Ying Du Sells Shares of Zai Lab Ltd (ZLAB)
Zai Lab Announces Dr. Harald Reinhart to Retire as Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases; Dr. Rafael Amado to be Appointed President, Head of Global R&D